Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

89.84EUR
4:35pm GMT
Change (% chg)

€0.98 (+1.10%)
Prev Close
€88.86
Open
€88.86
Day's High
€90.06
Day's Low
€88.76
Volume
438,582
Avg. Vol
579,189
52-wk High
€115.20
52-wk Low
€87.23

Latest Key Developments (Source: Significant Developments)

Merck KGaA ‍Receives Approval (Updated Registration) For Cladribine Tablets In Australia​
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Merck KGaA ::SAYS ‍RECEIVES APPROVAL (UPDATED REGISTRATION) FOR CLADRIBINE TABLETS IN AUSTRALIA​.  Full Article

Merck Says Anand Nambiar, MD, Assigned As Head Of Integrated Circuit Materials Unit Of Merck KGaA
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Merck Ltd ::SAYS ANAND NAMBIAR, MD, HAS ACCEPTED NEW ASSIGNMENT AS 'HEAD OF INTEGRATED CIRCUIT MATERIALS' UNIT OF MERCK KGAA.SAYS NAMBIAR TO REMAIN CO'S MD UNTIL MARCH 31, 2018.  Full Article

Merck KGAA, Darmstadt Announces FDA 510(K) Clearance Of Genea Biomedx’S Fertility Benchtop Incubator Geri
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Merck Kgaa ::MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI™.MERCK KGAA - U.S. COMMERCIAL AVAILABILITY FOR GERI ‍EXPECTED IN FIRST HALF OF 2018 ​.  Full Article

Merck KgaA Says FDA 510(K) Clearance Of Benchtop Embryo Incubator Geri
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MERCK KGAA ::ANNOUNCES FDA 510(K) CLEARANCE OF PARTNER GENEA BIOMEDX’S FERTILITY BENCHTOP INCUBATOR GERI.U.S. COMMERCIAL AVAILABILITY EXPECTED IN FIRST HALF OF 2018.  Full Article

Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced Gastric Cancer
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Pfizer Inc ::MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN GASTRIC 300 STUDY IN PATIENTS WITH PRE-TREATED ADVANCED GASTRIC CANCER.MERCK KGAA- ‍PHASE III JAVELIN GASTRIC 300 TRIAL DID NOT MEET ITS PRIMARY ENDPOINT ​.MERCK KGAA- ‍SAFETY PROFILE OF AVELUMAB WAS CONSISTENT WITH THAT OBSERVED IN OVERALL JAVELIN CLINICAL DEVELOPMENT PROGRAM​.MERCK KGAA - ‍OUTCOME OF JAVELIN GASTRIC 300 DOES NOT HAVE ANY IMPACT ON CURRENT AVELUMAB APPROVALS​.MERCK KGAA - ‍JAVELIN GASTRIC 300 DATA WILL BE FURTHER EXAMINED TO BETTER UNDERSTAND RESULTS; WILL BE SUBMITTED FOR PRESENTATION AT MEDICAL CONGRESS​.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

BRIEF-Merck KGaA, Samsung Biologics sign MoU on strategic alliance
Wednesday, 1 Nov 2017 

Corrects company name in headline:Says MilliporeSigma signs memorandum of understanding (MoU) with Samsung Biologics for strategic alliance on biopharma manufacturing, biologics process development‍​.The new MoU is an extension of one signed in 2014 that encompasses a long-term supply agreement.  Full Article

GSK will look at Pfizer, Merck consumer assets if offered for sale
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - GlaxoSmithKline CEO Emma Walmsley tells reporters::as world leader in consumer healthcare, we will look at Pfizer consumer health.bulking up consumer is one option but top priority is boosting pharma pipeline.moving forward with Brexit contingency planning, would like to know about transition asap.needs clarity on Brexit implementation phase of at least 2 years.not thinking of any relocation out of UK as a result of brexit.would also look carefully at German Merck consumer assets.new pharma head Miels very focused on launch of 3 critical new products.happy to continue to work with Novartis on consumer health or take over stake if Novartis wants to sell.  Full Article

Merck KGaA: Canadian patent office to grant patent application for CRISPR technology
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - MERCK KGAA ::MERCK KGAA - CANADIAN PATENT OFFICE TO GRANT MERCK KGAA, DARMSTADT, GERMANY'S PATENT APPLICATION FOR CRISPR TECHNOLOGY.FIRST PATENT ALLOWANCE FOR COMPANY’S CRISPR TECHNOLOGY IN NORTH AMERICA‍​.  Full Article

Merck KGaA enters immuno-oncology collaboration with F-Star
Sunday, 4 Jun 2017 

June 4 (Reuters) - Merck KGaA :Strengthens immuno-oncology portfolio through expansion of F-star collaboration including LAG-3/PD-L1 bispecific antibody- new strategic collaboration to develop and commercialize bispecific immuno-oncology antibodies.Announced a new strategic collaboration with biopharmaceutical company F-star, Cambridge, UK, for development and commercialization of five bispecific immuno-oncology antibodies.Beyond these five bispecific antibodies, Merck KGgaA, Darmstadt, Germany, will have further rights to replace, as well as to add to these antibodies using F-Star's bispecific antibody platform.  Full Article

BRIEF-Merck Signs Distribution Agreement With Avanti Polar Lipids

* MERCK SIGNS DISTRIBUTION AGREEMENT WITH AVANTI POLAR LIPIDS Source text for Eikon: Further company coverage: